NO20090290L - Polyvalent vaksine mot salmonid alfavirusinfeksjoner - Google Patents

Polyvalent vaksine mot salmonid alfavirusinfeksjoner

Info

Publication number
NO20090290L
NO20090290L NO20090290A NO20090290A NO20090290L NO 20090290 L NO20090290 L NO 20090290L NO 20090290 A NO20090290 A NO 20090290A NO 20090290 A NO20090290 A NO 20090290A NO 20090290 L NO20090290 L NO 20090290L
Authority
NO
Norway
Prior art keywords
salmonid alphavirus
composition
polyvalent vaccine
vaccine
vaccine against
Prior art date
Application number
NO20090290A
Other languages
English (en)
Other versions
NO333242B1 (no
Inventor
Trygve Meum Eliassen
Inge Tom Solbakk
Svein Alexandersen
Marit Rode
Anne Aas-Eng
Bernt Martinsen
Original Assignee
Pharmaq As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40469649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090290(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaq As filed Critical Pharmaq As
Priority to NO20090290A priority Critical patent/NO333242B1/no
Priority to CL2009000287A priority patent/CL2009000287A1/es
Priority to GB1219654.9A priority patent/GB2493662B/en
Priority to GB0901913.4A priority patent/GB2457158B/en
Priority to CA2653300A priority patent/CA2653300C/en
Priority to CA3090088A priority patent/CA3090088C/en
Publication of NO20090290L publication Critical patent/NO20090290L/no
Publication of NO333242B1 publication Critical patent/NO333242B1/no
Priority to NO2015019C priority patent/NO2015019I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1808—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Foreliggende oppfinnelse vedrører en sammensetning omfattende salmonid alfavirus eller et antigent og/eller immunogent materiale avledet derav, kombinert med én eller flere komponenter valgt fra gruppen bestående av: en levende, svekket eller drept bakterie, et virus som ikke er salmonid alfavirus, hvor nevnte virus fortrinnsvis er svekket eller inaktivert, en sopp, en parasitt og et antigent og/eller immunogent materiale avledet fra enhver av disse komponentene. Oppfinnelsen vedrører enn videre en doseringsform og en vaksine omfattende sammensetningen, og oppfinnelsen tilveiebringer anvendelse av sammensetningen i medisin. Oppfinnelsen vedrører også en fremgangsmåte for å fremstille en sammensetning eller en vaksine som beskrevet over, og en fremgangsmåte for å forbedre en polyvalent vaksine, omfattende å inkludere i den polyvalente vaksinen et svekket eller inaktivert salmonid alfavirus.
NO20090290A 2008-02-08 2009-01-20 Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus NO333242B1 (no)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NO20090290A NO333242B1 (no) 2008-02-08 2009-01-20 Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus
CL2009000287A CL2009000287A1 (es) 2008-02-08 2009-02-06 Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
GB1219654.9A GB2493662B (en) 2008-02-08 2009-02-06 Salmonid alphavirus vaccine
GB0901913.4A GB2457158B (en) 2008-02-08 2009-02-06 Polyvalent vaccine against salmonid alphavirus infections
CA2653300A CA2653300C (en) 2008-02-08 2009-02-06 Polyvalent vaccine against salmonid alphavirus infections
CA3090088A CA3090088C (en) 2008-02-08 2009-02-06 Polyvalent vaccine against salmonid alphavirus infections
NO2015019C NO2015019I1 (no) 2008-02-08 2015-08-03 Aeromonas salmonicida subspesie salmonicida,inaktivert/ Vibrio salmonicida,inaktivert/ Vibrio anguillarum serotype O1, inaktivert/Vibrio anguillarum serovar O2a, inaktivert/ Moritella viscosa, inaktivert/ Infeksiøs pankreasnekrosevirus (IPVN) serotype Sp/Laksespankreas sykdomsvirus (SPDV) stamme F93-125, inaktivert

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20080711 2008-02-08
NO20080885 2008-02-20
NO20090290A NO333242B1 (no) 2008-02-08 2009-01-20 Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus

Publications (2)

Publication Number Publication Date
NO20090290L true NO20090290L (no) 2009-08-10
NO333242B1 NO333242B1 (no) 2013-04-15

Family

ID=40469649

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20090290A NO333242B1 (no) 2008-02-08 2009-01-20 Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus
NO2015019C NO2015019I1 (no) 2008-02-08 2015-08-03 Aeromonas salmonicida subspesie salmonicida,inaktivert/ Vibrio salmonicida,inaktivert/ Vibrio anguillarum serotype O1, inaktivert/Vibrio anguillarum serovar O2a, inaktivert/ Moritella viscosa, inaktivert/ Infeksiøs pankreasnekrosevirus (IPVN) serotype Sp/Laksespankreas sykdomsvirus (SPDV) stamme F93-125, inaktivert

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2015019C NO2015019I1 (no) 2008-02-08 2015-08-03 Aeromonas salmonicida subspesie salmonicida,inaktivert/ Vibrio salmonicida,inaktivert/ Vibrio anguillarum serotype O1, inaktivert/Vibrio anguillarum serovar O2a, inaktivert/ Moritella viscosa, inaktivert/ Infeksiøs pankreasnekrosevirus (IPVN) serotype Sp/Laksespankreas sykdomsvirus (SPDV) stamme F93-125, inaktivert

Country Status (4)

Country Link
CA (2) CA2653300C (no)
CL (1) CL2009000287A1 (no)
GB (2) GB2493662B (no)
NO (2) NO333242B1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2688587B2 (en) 2011-03-25 2023-08-16 Intervet International B.V. Salmonid alphavirus vaccine
EP2895501B1 (en) * 2012-09-17 2017-01-18 Novartis Tiergesundheit AG Salmonid alphavirus and uses thereof
NO344938B1 (en) * 2018-12-13 2020-07-20 Patogen As Pancreas Disease Virus Markers
BE1028701B1 (nl) * 2020-10-13 2022-05-16 Poulpharm Bvba Werkwijze voor autovaccin productie en verkregen autovaccin
CN112877399B (zh) * 2021-01-20 2023-05-16 中国水产科学研究院黑龙江水产研究所 一种鲑鳟鱼致病菌药敏检测方法、药敏检测试剂盒及制备方法
CA3230802A1 (en) * 2021-08-31 2023-03-09 Zoetis Services Llc Attenuated alphavirus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0712926T3 (da) * 1994-10-18 2004-02-09 Akzo Nobel Nv Virus, der forårsager bugspytkirtelsygdom hos fisk
WO1999058639A2 (en) * 1998-05-08 1999-11-18 Akzo Nobel N.V. Structural proteins of fish pancreatic disease virus and uses thereof
WO2003101482A2 (en) * 2002-05-31 2003-12-11 Genesis Group Inc. Liposome vaccine formulations for fin-fish
DK179025B1 (da) * 2005-09-16 2017-08-28 Intervet Int Bv Fiskevaccine
CL2007001893A1 (es) * 2006-06-29 2008-01-04 Pharmaq As Proceso para cultivar una bacteria del genero piscirickettsia en un medio cultivo libre de celulas huesped; proceso para obtener dichas bacterias; vacuna que comprende dichas bacterias; y alimento que comprende dicha vacuna para la prevencion de infecciones en peces con bacterias del genero piscirickettsia.

Also Published As

Publication number Publication date
CA3090088A1 (en) 2009-08-08
CA2653300C (en) 2020-11-17
CA3090088C (en) 2023-01-31
GB201219654D0 (en) 2012-12-12
CA2653300A1 (en) 2009-08-08
NO333242B1 (no) 2013-04-15
GB2457158B (en) 2013-04-03
GB2493662B (en) 2013-04-17
CL2009000287A1 (es) 2010-08-27
GB0901913D0 (en) 2009-03-11
NO2015019I1 (no) 2015-08-10
GB2493662A (en) 2013-02-13
GB2457158A (en) 2009-08-12

Similar Documents

Publication Publication Date Title
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
MX2009006178A (es) Vacuna contra salmonela.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
NO20071609L (no) Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
MY169275A (en) Method of immunization against the four serotypes of dengue
AR063057A1 (es) Metodo de inmunizacion contra los 4 serotipos de dengue
NZ597000A (en) Compositions and methods for administration of vaccines against dengue virus
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
MX384875B (es) Método para obtener una vacuna de mycoplasma.
WO2013104995A3 (en) Compositions and methods for treating viral infections
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MX357538B (es) Vacunas para meningococo de serogrupo x.
MX2024006589A (es) Formulaciones de vacunas contra el coronavirus.
BR112015014250A2 (pt) método para imunizar um bebê, vacina de combinação e, kit
BR112013017939A2 (pt) composição imunogênica liofilizada termoestável, método de preparação de uma composição compreendendo um antígeno viral atenuado e vesículas e usos da composição ou formulação
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
RU2008144180A (ru) Вакцина против микоплазмы и prrsv
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
ERR Erratum

Free format text: I PATENTTIDENDE NR. 32/12 BLE PATENTSOKNAD NR. 20090290 FEILAKTIG KUNNGJORT ENDELIG HENLAGT. SOKNADENS STATUS ER UNDER BEHANDLING.

PDF Filing an opposition

Opponent name: INTERVET INTERNATIONAL BV, WIM DE KOERVERSTRAAT 35

Effective date: 20140114

BDEC Board of appeal decision

Free format text: KLAGEN FORKASTES. PATENT NUMMER 333242 OPPHEVES

Filing date: 20160318

Effective date: 20171031

SPCW Withdrawal, rejection or dismissal of supplementary protection certificate

Spc suppl protection certif: 2015019